SCHEMBL2675171

SCHEMBL2675171

CCN(CCN1CCCc2cc(Br)ccc21)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.48
▸ MEN1 O00255 5/20 0.48
▸ KMT2A Q03164 5/20 0.48
▸ MAPT P10636 5/20 0.48
▸ GAA P10253 3/20 0.48
▸ TP53 P04637 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CASP1 P29466 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ SMAD3 P84022 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ HPGD P15428 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ PDK1 Q15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675767 0.86 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL2675662 0.85 HDAC1 (0.42) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL2676188 0.83 NOS3 (0.52) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL2675751 0.78 NOS3 (0.54) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL21198484 0.76 HDAC1 (0.55) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL23128840 0.75 HSD17B3 (0.52) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL2675512 0.74 NOS3 (0.49) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL2674380 0.74 HDAC1 (0.42) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL27778577 0.74 HDAC1 (0.47) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL5940049 0.74 HDAC1 (0.46) ALDH1A1MEN1KMT2AMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173813-B2 selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants NEURAXON, INC. (CA) 2012-05-08 — — US disclosed
EP-2139886-A1 QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY Neuraxon Inc. (CA) 2010-01-06 — — EP disclosed
WO-2008116308-A1 QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-10-02 — — WO disclosed
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS1, NOS2, NOS3 ALDH1A1 1027/4885MEN1 3486/4885KMT2A 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback